Related Experiment Video
Updated: Mar 1, 2026
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Man Li1, Jing Liu1,2, Ying Bi1
1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Background:
Toll-like receptors play an integral role in the process of inflammatory response after ischemic injury. The therapeutic potential acting on TLRs is worth of evaluations. The aim of this review was to introduce readers some potential medications or compounds which could alleviate the ischemic damage via TLRs.
Methods:
Research articles online on TLRs were reviewed. Categorizations were listed according to the follows, methods acting on TLRs directly, modulations of MyD88 or TRIF signaling pathway, and the ischemic tolerance induced by the preconditioning or postconditioning with TLR ligands or minor cerebral ischemia via acting on TLRs.
Results:
There are only a few studies concerning on direct effects. Anti-TLR4 or anti-TLR2 therapies may serve as promising strategies in acute events. Approaches targeting on inhibiting NF-κB signaling pathway and enhancing interferon regulatory factor dependent signaling have attracted great interests. Not only drugs but compounds extracted from traditional Chinese medicine have been used to identify their neuroprotective effects against cerebral ischemia. In addition, many researchers have reported the positive therapeutic effects of preconditioning with agonists of TLR2, 3, 4, 7 and 9. Several trails have also explored the potential of postconditioning, which provide a new idea in ischemic treatments. Considering all the evidence above, many drugs and new compounds may have great potential to reduce ischemic insults.
Conclusion:
This review will focus on promising therapies which exerting neuroprotective effects against ischemic injury by acting on TLRs.
Insights
Toll-like receptors (TLRs) are key in inflammatory responses to ischemic injury. This review explores potential TLR-targeting drugs and compounds for neuroprotection against ischemic damage.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Toll-like receptors (TLRs) are critical mediators of inflammatory responses following ischemic injury.
- Targeting TLRs presents a promising therapeutic avenue for mitigating ischemic damage.
Purpose of the Study:
- To review potential medications and compounds that alleviate ischemic damage by modulating Toll-like receptor activity.
- To highlight therapeutic strategies acting directly on TLRs or their signaling pathways.
Main Methods:
- A comprehensive review of research articles focusing on Toll-like receptors (TLRs) in the context of ischemic injury.
- Categorization of methods included direct TLR action, modulation of MyD88/TRIF pathways, and TLR-induced ischemic tolerance via preconditioning/postconditioning.
Main Results:
- Direct anti-TLR4 and anti-TLR2 therapies show promise for acute ischemic events.
- Inhibition of NF-κB and enhancement of interferon regulatory factor signaling are of significant interest.
- Compounds from traditional Chinese medicine and preconditioning with TLR agonists (TLR2, 3, 4, 7, 9) demonstrate neuroprotective effects.
Conclusions:
- Various drugs and compounds targeting Toll-like receptors (TLRs) exhibit significant neuroprotective potential against ischemic injury.
- Modulating TLRs through direct action, pathway inhibition, or preconditioning offers promising therapeutic strategies for ischemic conditions.
